On the International Diabetes Day, which was held on November 14th Talde, through its investee Patia, joins in the promotion of research against this disease, whose evolution is increasingly alarming....
SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad de Princeton, ha recibido el galardón a la “Ronda de Inversión S...
The Riverside Company, a global private investor focused on the smaller end of the middle market, has signed a definitive agreement to acquire a controlling stake in BioDue S.p.A (BioDue), an Italian ...
La biofarmacéutica Oncostellae ha abierto una ronda de 3,3 millones de euros que destinará a completar los ensayos clínicos de dos moléculas para el tratamiento de enfermedades del tracto digestiv...
Oxolife, the Women’s Reproductive Health R&D biotech, has been awarded with a 2.4M€ grant from the Spanish Science and Innovation Ministry (Plan Estatal de Investigación Científica) to develop a...
Researchers at Pulmobiotics, a start-up founded in 2020 at the Centre for Genomic Regulation (CRG) in Barcelona backed by Invivo Ventures, have begun work on a ‘living medicine’ to improve the eff...
El CDTI Innovación, a través de su programa Innvierte, conjuntamente con Nuubo Investments FCRE y Fides Capital, han alcanzado un acuerdo con los socios de SMART SOLUTIONS TECHNOLOGIES, S.L. (NUUBO)...
Tetraneuron, compañía biotecnológica española que desarrolla una terapia génica con un enfoque multifactorial frente a la Enfermedad de Alzheimer y otras enfermedades neurodegenerativas, ha logra...
Ysios Capital, a European life sciences venture capital firm, has announced the promotions of Jordi Xiol to Partner and Salvatore Scaffidi to Associate, as well as the appointment of Joan Perelló as ...
In a year that looked uncertain at the start given the general drop in investment and valuations in markets worldwide, health startups and scaleups in Catalonia have once again set all-time records, s...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced th...
Asabys has announced the 1st closing of its 2nd fund, with commitments of €100 million. The firm’s goal is to reach €200 million this year, to invest in 12 to 15 companies in the EU, Israel, UK ...